Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C

Motoyuki Kohjima, Munechika Enjoji, Tsuyoshi Yoshimoto, Ryoko Yada, Tatsuya Fujino, Yoko Aoyagi, Nobuyoshi Fukushima, Kunitaka Fukuizumi, Naohiko Harada, Masayoshi Yada, Masaki Kato, Kazuhiro Kotoh, Manabu Nakashima, Naoya Sakamoto, Yasuhito Tanaka, Makoto Nakamuta

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Despite the use of pegylated-interferon (peg-IFN) plus ribavirin combination therapy, many patients infected with hepatitis C virus (HCV)-1b remain HCV-positive. To determine whether addition of pitavastatin and eicosapentaenoic acid (EPA) is beneficial, the "add-on" therapy option (add-on group) was compared retrospectively with unmodified peg-IFN/ribavirin therapy (standard group). Association of host- or virus-related factors with sustained virological response was assessed. In HCV replicon cells, the effects of pitavastatin and/or EPA on HCV replication and expression of innate-immunity- and lipid-metabolism-associated genes were investigated. In patients infected with HCV-1b, sustained virological response rates were significantly higher in the add-on than standard group. In both groups, sustained virological response rates were significantly higher in patients with genotype TT of IL-28B (rs8099917) than in those with non-TT genotype. Among the patients with non-TT genotype, sustained virological response rates were markedly higher in the add-on than standard group. By multivariate analysis, genome variation of IL28B but not add-on therapy remained as a predictive factor of sustained virological response. In replicon cells, pitavastatin and EPA suppressed HCV replication. Activation of innate immunity was obvious in pitavastatin-treated cells and EPA suppressed the expression of sterol regulatory element binding protein-1c and low-density lipoprotein receptor. Addition of pitavastatin and EPA to peg-IFN/ribavirin treatment improved sustained virological response in patients infected with HCV-1b. Genotype variation of IL-28B is a strong predictive factor in add-on therapy. J. Med. Virol. 85:250-260, 2013. © 2012 Wiley Periodicals, Inc.

元の言語英語
ページ(範囲)250-260
ページ数11
ジャーナルJournal of Medical Virology
85
発行部数2
DOI
出版物ステータス出版済み - 2 2013

Fingerprint

Eicosapentaenoic Acid
Ribavirin
Chronic Hepatitis C
Hepacivirus
Genotype
Interferons
Replicon
Virus Replication
Innate Immunity
Therapeutics
Sterol Regulatory Element Binding Protein 1
LDL Receptors
Group Psychotherapy
pitavastatin
Lipid Metabolism
Multivariate Analysis
Genome
Viruses
Genes

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

これを引用

Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. / Kohjima, Motoyuki; Enjoji, Munechika; Yoshimoto, Tsuyoshi; Yada, Ryoko; Fujino, Tatsuya; Aoyagi, Yoko; Fukushima, Nobuyoshi; Fukuizumi, Kunitaka; Harada, Naohiko; Yada, Masayoshi; Kato, Masaki; Kotoh, Kazuhiro; Nakashima, Manabu; Sakamoto, Naoya; Tanaka, Yasuhito; Nakamuta, Makoto.

:: Journal of Medical Virology, 巻 85, 番号 2, 02.2013, p. 250-260.

研究成果: ジャーナルへの寄稿記事

Kohjima, M, Enjoji, M, Yoshimoto, T, Yada, R, Fujino, T, Aoyagi, Y, Fukushima, N, Fukuizumi, K, Harada, N, Yada, M, Kato, M, Kotoh, K, Nakashima, M, Sakamoto, N, Tanaka, Y & Nakamuta, M 2013, 'Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C', Journal of Medical Virology, 巻. 85, 番号 2, pp. 250-260. https://doi.org/10.1002/jmv.23464
Kohjima, Motoyuki ; Enjoji, Munechika ; Yoshimoto, Tsuyoshi ; Yada, Ryoko ; Fujino, Tatsuya ; Aoyagi, Yoko ; Fukushima, Nobuyoshi ; Fukuizumi, Kunitaka ; Harada, Naohiko ; Yada, Masayoshi ; Kato, Masaki ; Kotoh, Kazuhiro ; Nakashima, Manabu ; Sakamoto, Naoya ; Tanaka, Yasuhito ; Nakamuta, Makoto. / Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. :: Journal of Medical Virology. 2013 ; 巻 85, 番号 2. pp. 250-260.
@article{ca5cfea969784fa0a420a87dcc02b954,
title = "Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C",
abstract = "Despite the use of pegylated-interferon (peg-IFN) plus ribavirin combination therapy, many patients infected with hepatitis C virus (HCV)-1b remain HCV-positive. To determine whether addition of pitavastatin and eicosapentaenoic acid (EPA) is beneficial, the {"}add-on{"} therapy option (add-on group) was compared retrospectively with unmodified peg-IFN/ribavirin therapy (standard group). Association of host- or virus-related factors with sustained virological response was assessed. In HCV replicon cells, the effects of pitavastatin and/or EPA on HCV replication and expression of innate-immunity- and lipid-metabolism-associated genes were investigated. In patients infected with HCV-1b, sustained virological response rates were significantly higher in the add-on than standard group. In both groups, sustained virological response rates were significantly higher in patients with genotype TT of IL-28B (rs8099917) than in those with non-TT genotype. Among the patients with non-TT genotype, sustained virological response rates were markedly higher in the add-on than standard group. By multivariate analysis, genome variation of IL28B but not add-on therapy remained as a predictive factor of sustained virological response. In replicon cells, pitavastatin and EPA suppressed HCV replication. Activation of innate immunity was obvious in pitavastatin-treated cells and EPA suppressed the expression of sterol regulatory element binding protein-1c and low-density lipoprotein receptor. Addition of pitavastatin and EPA to peg-IFN/ribavirin treatment improved sustained virological response in patients infected with HCV-1b. Genotype variation of IL-28B is a strong predictive factor in add-on therapy. J. Med. Virol. 85:250-260, 2013. {\circledC} 2012 Wiley Periodicals, Inc.",
author = "Motoyuki Kohjima and Munechika Enjoji and Tsuyoshi Yoshimoto and Ryoko Yada and Tatsuya Fujino and Yoko Aoyagi and Nobuyoshi Fukushima and Kunitaka Fukuizumi and Naohiko Harada and Masayoshi Yada and Masaki Kato and Kazuhiro Kotoh and Manabu Nakashima and Naoya Sakamoto and Yasuhito Tanaka and Makoto Nakamuta",
year = "2013",
month = "2",
doi = "10.1002/jmv.23464",
language = "English",
volume = "85",
pages = "250--260",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C

AU - Kohjima, Motoyuki

AU - Enjoji, Munechika

AU - Yoshimoto, Tsuyoshi

AU - Yada, Ryoko

AU - Fujino, Tatsuya

AU - Aoyagi, Yoko

AU - Fukushima, Nobuyoshi

AU - Fukuizumi, Kunitaka

AU - Harada, Naohiko

AU - Yada, Masayoshi

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Nakashima, Manabu

AU - Sakamoto, Naoya

AU - Tanaka, Yasuhito

AU - Nakamuta, Makoto

PY - 2013/2

Y1 - 2013/2

N2 - Despite the use of pegylated-interferon (peg-IFN) plus ribavirin combination therapy, many patients infected with hepatitis C virus (HCV)-1b remain HCV-positive. To determine whether addition of pitavastatin and eicosapentaenoic acid (EPA) is beneficial, the "add-on" therapy option (add-on group) was compared retrospectively with unmodified peg-IFN/ribavirin therapy (standard group). Association of host- or virus-related factors with sustained virological response was assessed. In HCV replicon cells, the effects of pitavastatin and/or EPA on HCV replication and expression of innate-immunity- and lipid-metabolism-associated genes were investigated. In patients infected with HCV-1b, sustained virological response rates were significantly higher in the add-on than standard group. In both groups, sustained virological response rates were significantly higher in patients with genotype TT of IL-28B (rs8099917) than in those with non-TT genotype. Among the patients with non-TT genotype, sustained virological response rates were markedly higher in the add-on than standard group. By multivariate analysis, genome variation of IL28B but not add-on therapy remained as a predictive factor of sustained virological response. In replicon cells, pitavastatin and EPA suppressed HCV replication. Activation of innate immunity was obvious in pitavastatin-treated cells and EPA suppressed the expression of sterol regulatory element binding protein-1c and low-density lipoprotein receptor. Addition of pitavastatin and EPA to peg-IFN/ribavirin treatment improved sustained virological response in patients infected with HCV-1b. Genotype variation of IL-28B is a strong predictive factor in add-on therapy. J. Med. Virol. 85:250-260, 2013. © 2012 Wiley Periodicals, Inc.

AB - Despite the use of pegylated-interferon (peg-IFN) plus ribavirin combination therapy, many patients infected with hepatitis C virus (HCV)-1b remain HCV-positive. To determine whether addition of pitavastatin and eicosapentaenoic acid (EPA) is beneficial, the "add-on" therapy option (add-on group) was compared retrospectively with unmodified peg-IFN/ribavirin therapy (standard group). Association of host- or virus-related factors with sustained virological response was assessed. In HCV replicon cells, the effects of pitavastatin and/or EPA on HCV replication and expression of innate-immunity- and lipid-metabolism-associated genes were investigated. In patients infected with HCV-1b, sustained virological response rates were significantly higher in the add-on than standard group. In both groups, sustained virological response rates were significantly higher in patients with genotype TT of IL-28B (rs8099917) than in those with non-TT genotype. Among the patients with non-TT genotype, sustained virological response rates were markedly higher in the add-on than standard group. By multivariate analysis, genome variation of IL28B but not add-on therapy remained as a predictive factor of sustained virological response. In replicon cells, pitavastatin and EPA suppressed HCV replication. Activation of innate immunity was obvious in pitavastatin-treated cells and EPA suppressed the expression of sterol regulatory element binding protein-1c and low-density lipoprotein receptor. Addition of pitavastatin and EPA to peg-IFN/ribavirin treatment improved sustained virological response in patients infected with HCV-1b. Genotype variation of IL-28B is a strong predictive factor in add-on therapy. J. Med. Virol. 85:250-260, 2013. © 2012 Wiley Periodicals, Inc.

UR - http://www.scopus.com/inward/record.url?scp=84871070984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871070984&partnerID=8YFLogxK

U2 - 10.1002/jmv.23464

DO - 10.1002/jmv.23464

M3 - Article

VL - 85

SP - 250

EP - 260

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 2

ER -